AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting

{
  "signal_id": "69ae216b-6a5e-ba7c-15a1-ca590fa44049",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-17T12:30:00+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/abbvie-to-present-phase-3-etentamig-results-and-data-from-broad-multiple-myeloma-portfolio-at-the-2026-international-myeloma-society-ims-meeting-302881330.html",
    "title": "AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting",
    "excerpt": "NORTH CHICAGO, Ill. , Sept. 17, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV ) announced today that new data from its broad multiple myeloma research portfolio will be featured at the 23 rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland. A plenary presentation will feature full results from the Phase 3 CERVINO study evaluating investigational drug etentamig, a second-generation BCMA x CD3 bispecific T-cell engager. Topline results demonstrated statistically significant and clinically meaningful improvements in objective response rate (ORR) and progression-free survival (PFS), with etentamig meeting the dual primary endpoints versus standard available therapies in adults with triple-class exposed relapsed/refractory multiple myeloma (RRMM). Beyond the full CERVINO data, AbbVie will present research demonstrating the breadth of its myeloma pipeline across T-cell engagers, targeted therapies, rational combinations and real-world evidence. Presentations will feature investigational assets including ABBV-2001 (ISB 2001), a CD38 x BCMA x CD3 trispecific T-cell engager, and surzetoclax, a BCL-2 small-molecule inhibitor, alongside studies evaluating etentamig across multiple treatment settings. Additional presentations from these investigational assets will explore treatment sequencing, infection-related healthcare utilization...",
    "product": "ABBV-2001 (ISB 2001)",
    "summary": "AbbVie is developing ABBV-2001 (ISB 2001), a CD38 x BCMA x CD3 trispecific T-cell engager, as part of its multiple myeloma pipeline.",
    "location": "North Chicago, IL",
    "planning": true,
    "confidence": 0.8,
    "product_data": {
      "name": "ABBV-2001 (ISB 2001)",
      "full_text": "ABBV-2001 (ISB 2001), a CD38 x BCMA x CD3 trispecific T-cell engager",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology",
      "future_tech"
    ],
    "published_at": "2026-09-17T12:30:00Z",
    "location_data": [
      {
        "city": "North Chicago",
        "state": "Illinois",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Presentations will feature investigational assets including ABBV-2001 (ISB 2001), a CD38 x BCMA x CD3 trispecific T-cell engager, and surzetoclax, a BCL-2 small-molecule inhibitor, alongside studies evaluating etentamig across multiple treatment settings."
  }
}

curl https://signals.autobound.ai/v1/signals/69ae216b-6a5e-ba7c-15a1-ca590fa44049 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","limit":20}'